Literature DB >> 19632228

Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program.

Ricardo G Gurgel1, Anna K Bohland, Sarah C F Vieira, Débora M P Oliveira, Paula B Fontes, Viviane F Barros, Marcela F Ramos, Winifred Dove, Toyoko Nakagomi, Osamu Nakagomi, Jailson B Correia, Nigel Cunliffe, Luis E Cuevas.   

Abstract

BACKGROUND & AIMS: Rotavirus vaccines were introduced in Brazil in 2006; we evaluated their effects in the state of Sergipe, Brazil.
METHODS: We performed a cross-sectional survey of children with diarrhea attending emergency services in Aracaju, Brazil, between October 2006 and April 2008 and a cluster sampling survey to assess vaccination coverage. Vaccine efficacy was assessed using the screening method. Diarrhea consultation and hospitalization data (2003-2007) were obtained from state and national surveillance systems.
RESULTS: Rotavirus was detected in 59 of 534 stool samples (11%) from children attending emergency services. The number of rotavirus-positive samples decreased from 18 of 74 (24%) in 2006 to 31 of 321 (9.5%) in 2007 and 10 of 136 (7.4%) in 2008 (P < .01). Diarrhea severity was greater in children with rotavirus (P < .01) but decreased over time (P < .001). Of the rotaviruses detected, 56 of 59 (95%) were P[4]G2 genotype, 1 was P[4]G-non-typeable (NT), 1 was P[NT]G2, and 1 was P[NT]GNT. Diarrhea consultations decreased from 3020 in 2004 to 604 in 2007; reductions were greatest among children under 5 years old. Diarrhea hospitalizations decreased from 2121 in 2003 to 1176 in 2007. Vaccine coverage was 90.3%. Vaccines were highly effective against the strain P[8]G1; efficacy against P[4]G2 genotype was 89% (95% confidence interval: 0.87-0.92) in Aracaju and 95% in Sergipe.
CONCLUSIONS: Since vaccines were introduced in 2006, there has been an overall reduction in diarrhea consultations and hospitalizations in northeast Brazil, with the greatest reductions in young children. This might have resulted from vaccination and improved sanitation. Although a single rotavirus genotype (P[4]G2) was recovered, vaccine efficacy was high against this genotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632228     DOI: 10.1053/j.gastro.2009.07.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  32 in total

1.  Changing patterns of rotavirus genotypes in Turkey.

Authors:  Anil Tapisiz; Zeynep Ceren Karahan; Ergin Çiftçi; Erdal İnce; Ülker Doğru
Journal:  Curr Microbiol       Date:  2011-09-22       Impact factor: 2.188

2.  Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions.

Authors:  Virginia E Pitzer; Manish M Patel; Ben A Lopman; Cécile Viboud; Umesh D Parashar; Bryan T Grenfell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

Review 3.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

Review 4.  Rotavirus diversity and evolution in the post-vaccine world.

Authors:  John T Patton
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

Review 5.  Rotavirus vaccines: current status and future considerations.

Authors:  Catherine Yen; Jacqueline E Tate; Terri B Hyde; Margaret M Cortese; Benjamin A Lopman; Baoming Jiang; Roger I Glass; Umesh D Parashar
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

Review 6.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

7.  Molecular-Genetic Characterization of Human Rotavirus A Strains Circulating in Moscow, Russia (2009-2014).

Authors:  Victoria Kiseleva; Evgeny Faizuloev; Elena Meskina; Anna Marova; Alexey Oksanich; Tatiana Samartseva; Georgy Bakhtoyarov; Natalia Bochkareva; Nikolay Filatov; Andrey Linok; Yulia Ammour; Vitaly Zverev
Journal:  Virol Sin       Date:  2018-07-30       Impact factor: 4.327

8.  Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix: approach and outcome.

Authors:  Gary Dubin; Jean-François Toussaint; Jean-Pol Cassart; Barbara Howe; Donna Boyce; Leonard Friedland; Remon Abu-Elyazeed; Sylviane Poncelet; Htay Htay Han; Serge Debrus
Journal:  Hum Vaccin Immunother       Date:  2013-08-28       Impact factor: 3.452

9.  Laboratory-Confirmed Rotavirus Disease in Utah Children: Clinical and Economic Impact of Rotavirus Vaccination.

Authors:  Angel Herrera Guerra; Chris Stockmann; Andrew T Pavia; Adam L Hersh; Emily A Thorell; Hsin Yi Weng; Kent Korgenski; Carrie L Byington; Krow Ampofo
Journal:  J Pediatric Infect Dis Soc       Date:  2012-06-22       Impact factor: 3.164

10.  Molecular epidemiology of contemporary G2P[4] human rotaviruses cocirculating in a single U.S. community: footprints of a globally transitioning genotype.

Authors:  Allison F Dennis; Sarah M McDonald; Daniel C Payne; Slavica Mijatovic-Rustempasic; Mathew D Esona; Kathryn M Edwards; James D Chappell; John T Patton
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.